Monday, June 27, 2022

GB Sciences Inc (OTCMKTS:GBLX) Cannabis Mover and Shaker

GB Sciences Inc (OTCMKTS:GBLX) looks to be a newly trading cannabis name on the scene who recently partnered with Arizona-based Kush Cups when they signed an agreement to produce cannabis-infused products in the state of Nevada. They also submitted an offer to Louisiana State University to act as the LSU licensed operator of their medical cannabis production facility, they have been busy.

GB Sciences utilizes advanced propagation technology, raw tissue, and grows in medical-grade clean rooms, so that the venture is ensured of consistent cannabis ingredients for its infused products.

“We’ve paired with a strong partner here. We are confident GB Sciences will distribute the Kush Cups successfully in Nevada,” said Rick Chavez, founder of Kush Cups Nevada LLC.

GB Sciences Inc (OTCMKTS:GBLX) will grow the cannabis in their state-of-the-art Cultivation Labs facility in Las Vegas and distribute cannabis-infused Keurig-compatible K-Cups, hot and cold brew coffees as well as infused teas.

Subscribe below and we’ll keep you on top of what’s happening before $GBLX stock makes its next move.

$GBLX 10-Day Chart Below:

“We’re excited to join forces with Kush Cups. They have an excellent line of products and are the leaders in their space in Nevada,” 
said GB Sciences CEO John Poss. “Our partnership is positioned for maximum impact in the Nevada market.  It is the first major step in our strategy to be a trusted ingredient in leading brands of infused products and therapies.”

With over 15 years of marijuana edible manufacturing experience, the team at Kush Cups sources the highest quality strains in the manufacturing of the best medicinal coffee and teas in the industry, and is the only manufacturer producing products compatible for Keurig machines.

The company also in recent PR said, they submitted an offer to Louisiana State University to act as the LSU licensed operator of their medical cannabis production facility as outlined in the Alison Neustrom Act. The offer would enable GB Sciences to be the sole vendor of cannabis and extracted cannabis compounds on behalf of LSU for the patients of Louisiana. LSU and Southern University have the only two licenses granted by the State of Louisiana to cultivate, distribute, and sell medical cannabis.

The Act specifically authorizes the LSU AgCenter to conduct research on medical cannabis. The AgCenter will operate a separate research division for independent research. The research division may operate alongside and in the same facility as the Production Entity’s commercial operation, which will produce therapeutic medical cannabis products for qualified patients of Louisiana. If GB Sciences is selected to work with LSU, it will have first rights to commercialize any inventions or discovery of research center. GB Sciences is looking forward to the prospect of working with LSU on GB Sciences’ cannabis tissue propagation technology. The facility will serve the approximate five million people who live in the state of Louisiana. The cultivation plant will contain a minimum of a 5,000 square foot research lab.

In order to fulfill the requirements of the application, GBLX is raising two million dollars in bonds. The bonds will collateralize a required bid bond associated with the offer to LSU. This is an open bid process with only a few offers due to the one million dollar bid bond provision. The license and partnership is for the development of new cannabis based medical compounds and tissue propagation development for new cannabis drug discovery to advance the GB Sciences patented formulations toward FDA approved Clinical Trials.

GB Sciences, Inc. (OTCMKTS:GBLX) is new on the block and has only a short trading track record to rely on, but the industry itself is expected to grow from its current 400 public companies to 1500 by this time next year as the gold rush of green engulfs the investing world.  This company is focused on standardized cultivation and production methods; as well as biopharmaceutical research and development.

The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions, and is one worth watching. Stay tuned to the growing field of cannabis investing as it nears the eventual federal legalization all investors are betting on. For continuing coverage on shares of $GBLX stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!


Related Articles


Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles